Identification | Back Directory | [Name]
L-701,324 | [CAS]
142326-59-8 | [Synonyms]
L-701 CS-2045 L-701,324 L-701,304 7-Chloro-4-hydroxy-3-(3-phenoxy)phenyl-2(H)-quinolinone 7-chloro-1-(4-hydroxy-3-phenoxyphenyl)quinolin-2(1H)-one 7-CHLORO-4-HYDROXY-3-(3-PHENOXY)PHENYL-2(1H)-QUINOLINONE 7-chloro-4-hydroxy-3-(3-phenoxyphenyl)-1H-quinolin-2-one 7-CHLORO-4-HYDROXY-3-(3-PHENOXY )PHENYLQUINOLIN-2[1H]-ONE 2(1H)-Quinolinone, 7-chloro-4-hydroxy-3-(3-phenoxyphenyl)- | [Molecular Formula]
C21H14ClNO3 | [MDL Number]
MFCD00910917 | [MOL File]
142326-59-8.mol | [Molecular Weight]
363.79 |
Chemical Properties | Back Directory | [Melting point ]
308 °C | [Boiling point ]
584.7±50.0 °C(Predicted) | [density ]
1.389±0.06 g/cm3(Predicted) | [storage temp. ]
Sealed in dry,Room Temperature | [solubility ]
DMSO: soluble36.4mg/mL | [form ]
solid | [pka]
4.50±1.00(Predicted) | [color ]
White to off-white |
Hazard Information | Back Directory | [Uses]
L-701,324 is a potential anticonvulsant with high selectivity and affinity for the NMDA receptor glycine site. NMDA receptors are expressed by small-cell lung cancer and are potential targets for effective treatment. | [Definition]
ChEBI: 7-chloro-4-hydroxy-3-(3-phenoxyphenyl)-1H-quinolin-2-one is a member of quinolines. | [Biological Activity]
An orally active and long acting anticonvulsant with high affinity and selectivity for the glycine site on the NMDA receptor. | [in vivo]
L-701324 (5-10 mg/kg; i.p.; once) exhibits antidepressant-like potential in the forced swim test (FST) and tail suspension test (TST) without affecting the locomotor activity of mice[1].
L-701324 (5-10 mg/kg; i.p.; daily, for 2 weeks) produces strong antidepressant-like effects in the chronic unpredictable mild stress (CUMS) model of depression and prevents the CUMS-induced decreases in eurogenesis and the BDNF signaling cascade in the hippocampus[1].
L-701324 (2.5-5 mg/kg; p.o.; once) inhibits NMDA receptor activity via a blockade of the NMDA/glycine-sensitive site at the NMDA receptor is accompanied by a reduction of anxiety-like behavior in both non-conditioned and conditioned conflict behavior situations[2].
Animal Model: | Male C57BL/6 J mice in the chronic unpredictable mild stress (CUMS) (7 weeks of age) [1] | Dosage: | 5 and 10 mg/kg | Administration: | Intraperitoneal injection; daily, for 2 weeks | Result: | Reduced the immobility of C57BL/6 J mice.
Increased the expression of BDNF, pTrkB and pCREB in the hippocampus.
|
Animal Model: | Male C57BL/6 J mice in the forced swim test (FST) and tail suspension test (TST) (7 weeks of age)[1] | Dosage: | 5 and 10 mg/kg | Administration: | Intraperitoneal injection; once | Result: | Reduced the immobility of C57BL/6 J mice in the FST and TST.
|
Animal Model: | Male Sprague-Dawley rats (280-300 g)[2] | Dosage: | 2.5 and 5 mg/kg | Administration: | Oral administration; once | Result: | Increased in the percentage of time spent in the open arm in a dose-dependent.
Increased punished responding in the Vogel's conflict test in a dose-dependent fashion.
|
| [IC 50]
NMDA Receptor | [storage]
Store at RT |
|
|